Murphy Pohlad Asset Management LLC Decreases Stock Holdings in Pfizer Inc. $PFE

Murphy Pohlad Asset Management LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 29.5% during the 3rd quarter, Holdings Channel reports. The firm owned 82,436 shares of the biopharmaceutical company’s stock after selling 34,459 shares during the period. Murphy Pohlad Asset Management LLC’s holdings in Pfizer were worth $2,100,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after acquiring an additional 10,198,330 shares during the period. Geode Capital Management LLC increased its stake in shares of Pfizer by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after purchasing an additional 1,820,634 shares during the last quarter. Norges Bank bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $2,270,157,000. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 2.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after purchasing an additional 1,135,457 shares during the last quarter. Finally, Fisher Asset Management LLC grew its holdings in Pfizer by 2.0% during the second quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock valued at $1,172,980,000 after purchasing an additional 950,239 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research reports. UBS Group initiated coverage on Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price on the stock. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Citigroup started coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. Finally, Scotiabank started coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.06.

Pfizer Price Performance

PFE stock opened at $27.24 on Friday. The firm has a 50 day moving average of $25.61 and a 200-day moving average of $25.10. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The firm has a market capitalization of $154.88 billion, a P/E ratio of 20.03 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the prior year, the firm posted $0.63 earnings per share. The business’s quarterly revenue was down 1.2% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and GLP‑1 topline: Pfizer reported upside on revenue and EPS and released positive Phase 2b results for its lead GLP‑1 candidate (strong placebo‑adjusted weight loss), which helped lift sentiment around a new growth leg. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: Management outlines obesity strategy: Pfizer execs signaled the company is “back in the obesity race,” emphasizing development plans and commercialization intent after the encouraging GLP‑1 data. Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
• Positive Sentiment: FDA grants Priority Review for HYMPAVZI sBLA: The agency accepted a supplemental biologics license application to expand HYMPAVZI’s indication to pediatric and inhibitor populations in hemophilia, which could broaden revenue opportunity if approved. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Mid‑stage obesity candidate complete: Pfizer announced completion of a mid‑stage trial for PF‑07976016, adding to its GLP‑1/obesity development cadence and potential registration pathway. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
• Positive Sentiment: Pipeline & M&A push into oncology and obesity: Analysts and coverage note Pfizer is lining up ~20 pivotal studies after ~ $9B of 2025 M&A, leaning on Seagen assets and AI tools to accelerate R&D — a multi‑year growth story. Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
• Positive Sentiment: Income investor attention: Pfizer appears on recent high‑yield dividend stock lists, which can support demand from yield‑focused investors. 3 High-Yield Dividend Stocks Perfect For Retirees
• Neutral Sentiment: Cost‑savings / affordability program: Pfizer launched a TrumpRx program offering discounts on ~30 medicines — positive for patient access and PR, but the near‑term financial impact is unclear. Pfizer Launches Cost-Savings Program on TrumpRx
• Neutral Sentiment: Analyst views mixed: Coverage notes cautious upside — bullish pipeline/AI drivers balanced by execution risk, time to commercialization, and competitive pressure in GLP‑1s. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Negative Sentiment: Early‑stage trial halted: Pfizer paused an early‑stage study for PF‑07258669 in older adults, introducing a specific clinical risk that could require program adjustments. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.